top of page
CartilaGen Logo Blue.png

Changing the paradigm of osteoarthritis treatment

knee cover slide.png

OUR SOLUTION

Routine intra-articular injection procedure of a small-molecule drug into a joint cavity after traumatic injury to prevent osteoarthritis
First-mover that fulfills a major unmet medical need!
TECHNOLOGY

News

pappajohn competition.jpg
Competition

CartilaGen Wins Pappajohn Iowa Entrepreneurial Venture Competition

NEWS

About CartilaGen

THE PROBLEM
  • Posttraumatic osteoarthritis (PTOA) is the number one disabling condition leading to medical discharge of wounded warriors from active duty

  • PTOA affects over six million civilians at a cost of nearly $15 billion annually to the United States

  • PTOA has devastating effects on patients and current treatment options are limited and ineffective before end-stage joint replacement

OUR VISION
  • Drug-eluting, bioactive hydrogel proven effective for PTOA prevention

  • Targets the earliest stage of PTOA development and treats the underlying disease mechanism in an easily performed, cost-effective manner

  • Designed for cartilage injuries and early stage osteoarthritis

  • Combined Phase I/IIa clinical trial scheduled

OUR PARTNERS
  • University of Iowa Hospitals and Clinics

  • Indiana University Health

  • US Department of Defense

  • METRC (Major Extremity Trauma and Rehabilitation Consortium)

ABOUT
CONTACT
bottom of page